MIPS Molecular Imaging Program at Stanford
Center for Cancer Nanotechnology Excellence Focused on Therapy Response


	Andrew Ellington, Ph.D.Andrew Ellington, Ph.D.
Investigator: Project 4
Professor, Department of Chemistry and Biochemistry
University of Texas at Austin
1 University Station A5300
Austin, TX 78712-0165

Phone: (512) 232-3424
Fax: (512) 471-7104

Email: andy.ellington@mail.utexas.edu

Investigator: Project 4, Professor, Fraser Professor of Chemistry and Biochemistry (University of Texas)
Research in Dr. Ellington's laboratory uses in vitro evolution to engineer biopolymers and cells. The Ellington lab has developed diagnostic and therapeutic reagents known as aptamers (nucleic acid binding species) and aptazymes (allosteric ribozymes). The lab focuses on real-world diagnostic and therapeutic applications of these reagents, including inhibiting HIV replication and detecting biothreat agents such as the toxin ricin. In addition, the lab maintains an Automated Selection Facility in order to select aptamers against other targets, such as tumor markers and cells. In order to adapt molecular recognition and targeting technologies to applications involving nanoparticles, the Ellington lab has previously collaborated with researchers (such as Brian Korgel, in the Department of Chemical Engineering) and companies (such as Evident Technologies) that are involved in the production of nanoparticles such as quantum dots.

Footer Links: